Gallego demands answers on Eli Lilly’s deal with Trump
Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly CEO David Ricks, provided first to The Hill, Gallego wrote that “substantial questions remain” pertaining to the deal that the White House struck with…
Drug Cuts Nausea From GLP-1 Drugs; ‘Female Viagra’ Boom; Semaglutide and Alcohol Use
(MedPage Today) — Vanda Pharmaceuticals said its investigational neurokinin-1 receptor antagonist tradipitant reduced nausea and vomiting from semaglutide (Ozempic, Wegovy) in a randomized trial of people with obesity or overweight. A KFF poll…
Can AI Drive Peloton’s Comeback?
In this podcast, Motley Fool contributors Travis Hoium, Rachel Warren, and Jon Quast discuss: Pfizer buying Metsera. Peloton‘s comeback. Circle‘s growth and why Coinbase is a winner. To catch full episodes of all The Motley Fool’s free podcasts, check out our podcast center. When you’re ready to invest, check out this top 10 list of […]
How Ozempic Is Changing Thanksgiving
Thanks to the GLP-1 revolution, families across the country are negotiating new ways to connect over the holidays.
Factor in Eli Lilly weight-loss drug could help treat certain eating disorders, study finds
Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the “reward center” of the brain.
The surprising new use for GLP-1s: Alcohol and drug addiction – The Washington Post
The surprising new use for GLP-1s: Alcohol and drug addiction The Washington Post Taking Ozempic? Yale Researchers Say You’ll Handle Alcohol “Differently” and It Could Be Risky SciTechDaily Doctor finds new use for GLP-1s: Alcohol, drug addiction NewsNation Opinion | Do you take a GLP-1 for alternative uses? Tell us about it. The New York Times The ‘magic’ medicine: […]
Vanda’s tradipitant can significantly reduce nausea in those taking a GLP-1
Vanda tackles Wegovy-driven vomiting, sparking race to phase 3
Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing up to start a phase 3 trial in the setting in the first half of next year.
High-Protein Snacks for GLP-1 Users
You might recognize this scene. Lunch was small, you feel full sooner than usual, and by late afternoon you are both a little hungry and a little uninterested in a full plate. That’s a common GLP-1 experience. One trick is to keep a short list of satisfying, easy snacks that slip into your day and […]
The ‘magic’ medicine: Can weight-loss drug GLP-1 treat alcohol and drug addiction?
Originally developed for diabetes, GLP-1 drugs like Ozempic are showing remarkable potential in combating addiction. Emerging research suggests these medications can dampen cravings for alcohol and drugs by influencing the brain’s reward system. While still in early stages, clinical trials and early patient experiences indicate a significant new therapeutic avenue for addiction treatment, offering hope […]